Cannbit to sell medical cannabis to Tikun Olam

medical cannabis
medical cannabis

Tikun Olam will be short of cannabis until its Kfar Yehoshua farms is approved.

Israeli cannabis cultivation company Cannbit (TASE: CPHO) announced that it will produce NIS 4.8 million worth of cannabis for Tikun Olam, the leading private company in the Israeli cannabis market. The share price of A.L. Capital Holdings (2016) Ltd. (TASE:CPHO.M), into which Cannbit was merged, has risen 42% over the past two days, boosting its market cap to NIS 97 million. Under the agreement, Cannbit will produce one cannabis crop for Tikun Olam for NIS 2.4 million, with an option for another NIS 2.4 million crop.

Tikun Olam produces cannabis at two sites: a farm in Biriya that does not meet the production standards under the new cannabis reform and a farm in Kfar Yehoshua that was designed to meet the standards, but has yet to be approved. Tikun Olam's production in Biriya was recently restricted when the Ministry of Health found alleged health defects on the farm. At this stage, the defects are still being tested. The Ministry of Health is allowing Tikun Olam to make only limited supervised deliveries from Biriya. The result is a cannabis shortage and a loss of customers for Tikun Olam.

The current agreement is not meant to immediately compensate for the potential shortage, because at this stage, Cannbit also does not have approval and is unable to produce medical cannabis. The company said that it hoped to harvest its first cannabis in early 2019. At the same time, Cannbit still requires approval from the Ministry of Health for its facilities in order to do this. It appears that Tikun Olam is preparing a backup in case the Kfar Yehoshua farm is not approved by the Ministry of Health or cannabis production there is inadequate for its needs.

Under the agreement, Cannbit will grow Tikun Olam's two unique cannabis strains on the basis of the growing protocol developed by Tikun Olam. Growth will be up until the wet plant is harvested, while Tikun Olam will be responsible for drying and processing it. If Tikun Olam is unable to use the Kfar Yehoshua farm under the new cannabis regulations, it will also be unable to process the cannabis there and sell cannabis.

Not all of the companies are ready for the reform

The new cannabis reform took effect in April 2018, and is currently being enforced simultaneously with the decade-old previous regulations. Under the new reform, growing licenses and setting up cannabis factories will be granted to dozens of farmers and producers, in contrast to only eight groups under the old regulations.

In order to sell a cannabis product under the new reform, it must be grown on an approved farm, manufactured in an approved factory, transported via an approved distribution company, and sold in an approved pharmacy.

The Ministry of Health recently notified the companies that any party not complying with the reform by March 31, 2019 would not be able to continue selling under the old regulations, even if it did so previously, and is liable to lose its cannabis license completely.

The only veteran companies in the cannabis market with approval to grow cannabis under the reform are Canndoc, Breath of Life (BOL) Pharma, and Seach. BOL also has a production facility, while Seach and Canndoc currently produce through Panaxia. Tikun Olam is currently establishing a farm (but not a factory) at Kfar Yehoshua, and Better Medical Grade Cannabis and Pharmocann, which recently entered the TASE by merging with WhiteSmoke (TASE: WSMK), have not yet received their approval under the new reform.

Together Startup Network Ltd.(TASE:TGTR), Medivie Therapeutic Ltd. (TASE:MDVI), Tefen (TASE: TFN), UNIVO Pharmaceuticals (TASE: UNVO), and Capital Holdings (Cannbit), the new players in the market, plan to operate under the new reform from the start. They have approval in principle for doing so, but not final approval from the Ministry of Health for their active growing sites. The same is true of Cannassure Therapeutics, which merged with Direct Capital Investments (TASE: DCI-M); the company has approval in principle for conversion to a cannabis factory, but still lacks final approval for the produce from it.

Published by Globes, Israel business news - en.globes.co.il - on December 5, 2018

© Copyright of Globes Publisher Itonut (1983) Ltd. 2018

medical cannabis
medical cannabis
groundcover founders credit: Yossi Yarom Israeli observability co groundcover raises $35m

groundcover has developed a “Bring Your Own Cloud” (BYOC) observability solution, redefining the architecture of a modern observability platform.

Tel Aviv Stock Exchange credit: Shutterstock MagioreStock Foreign investment in TASE hits five-year high

Foreign investors have been flocking to the Tel Aviv Stock Exchange in recent weeks, the TASE research department tells "Globes."

Elbit Systems tank turret systems credit: Elbit Systems Elbit Systems wins $100m tank turret systems deal

The Israel defense electronics company will supply its advanced UT30 MK2 unmanned turret systems to General Dynamics European Land Systems (GDELS) to be supplied to a NATO European country.

Tomer Weingarten Photo: PR Trump targets SentinelOne exec in act of revenge

The US administration has suspended the security clearance of the company's chef intelligence and public policy officer Chris Krebs and everyone associated with him.

Tel Aviv Stock Exchange share prices rising credit: Tali Bogdanovsky TASE opens sharply higher after Trump U-turn on tariffs

The pause is being interpreted as a climb down after US President Donald Trump admitted he had made the move to calm the markets.

Ashot Ashkelon credit: Ministry of Defense Up 250%, Ashot Ashkelon wins another Defense Ministry order

The Israeli defense company's share price has risen 250% in the past three years since FIMI Opportunity Funds acquired control.

Liad Agmon credit: Eyal Izhar Insight Partners Liad Agmon steps down as managing partner

Serial entrepreneur Agmon has served as a partner at Insight Partners Israel alongside Daniel Aronovitz who set up the Israel office.

Shekels credit: Shutterstock Vladerina32 Shekel slide resumes amid escalating tariff war

The Bank of Israel is not expected to intervene in the forex market despite the sharp depreciation of the shekel.

Nir Zuk credit: Inbal Marmari Palo Alto Networks mulls buying AI security co for $700m

Sources inform "Globes" that on Palo Alto's radar is Protect AI.

President Donald Trump hosts Prime Minister Benjamin Netanyahu credit: Reuters Kevin Mohatt Israeli officials confident on US tariff concessions

Senior Israeli figures believe that concessions could be tied to progress on strategic regional political issues that are important to President Trump.

Phoenix Investment House CEO Avner Hadad  credit: Tommy Harpaz "The market has priced in all the bad things"

Phoenix Investment House CEO Avner Hadad says US markets could continue to fall, but that we are close to interesting territory for patient investors.

Tel Aviv credit: Shutterstock Tel Aviv slips in World's Wealthiest Cities ranking

Tel Aviv's position as one of the world's wealthiest cities took a big knock over the past year as it slipped from 42nd to 48th in investment advisors Henley & Co.'s "World's Wealthiest Cities" Top 50 ranking.

Leviathan platform  credit: Albatross C'ttee seen recommending no cut in gas exports

The Dayan committee on the future of the gas sector estimates that Israel's natural gas reserves will run out in 2045.

Accountant General Yali Rothenberg credit: Rafi Kutz Israel's fiscal deficit continues to narrow

The deficit narrowed in the twelve months to the end of March 2025, for the sixth consecutive month, Ministry of Finance accountant general Yali Rothenberg reported today.

Arkia credit: Arkia Arkia cuts Tel Aviv - New York April fares

Arkia has cut fares at the last minute, a time when prices usually soar even higher, according to the pricing method used in the industry.

Bank of Israel Governor Prof. Amir Yaron credit: Dani Shem Tov Knesset Spokesperson BoI Governor: US tariffs could push up inflation in Israel

Prof. Amir Yaron tells "Globes" that there is a risk that the new tariffs will cause inflation to rise in the US, with a knock-on effect for Israel.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018